Schizophrenia as a subject of competence of psychiatrist, narcologist, cardiologist, endocrinologist and pathologist

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Numerous studies show that people with schizophrenia live 10–25 years less than the general population. The significant reduction in life expectancy is due to suicides, frequent comorbidity with heart and vascular diseases, metabolic disorders, including obesity and type 2 diabetes, as well as side effects of second-generation antipsychotics. Conditions for reducing the number of premature deaths in schizophrenia include changing the lifestyle of patients with improved nutrition and increased physical activity, increasing patient adherence to antipsychotic therapy with monitoring of the side effects of second-generation antipsychotics, as well as to the treatment of comorbid substance use disorders and comorbid somatic diseases.

About the authors

Yury P. Sivolap

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: yura-sivolap@yandex.ru
Russian Federation, 119991, Moscow, Trubetskaya str., 8 (2)

Anna A. Portnova

The Serbsky State Scientific Center for Social and Forensic Psychiatry

Email: aapserbsky@yandex.ru
Russian Federation, 119034, Moscow, Kropotkinsky lane, 23 (1)

Maxim V. Yanushkevich

I.M. Sechenov First Moscow State Medical University

Email: yura-sivolap@yandex.ru
Russian Federation, 119991, Moscow, Trubetskaya str., 8 (2)

Vladimir A. Savchenkov

I.M. Sechenov First Moscow State Medical University

Email: yura-sivolap@yandex.ru
Russian Federation, 119991, Moscow, Trubetskaya str., 8 (2)

Pavel V. Pushin

I.M. Sechenov First Moscow State Medical University

Email: yura-sivolap@yandex.ru
Russian Federation, 119991, Moscow, Trubetskaya str., 8 (2)

References

  1. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008; 4: 189–216. doi: 10.1146/annurev.clinpsy.4.022007.141248.
  2. Castle D.J., Buckley P.F. Schizophrenia. Second revised edition. Oxford: Oxford University Press. 2012; 132 p.
  3. Marcsisin M.J., Rosenstock J.B., Gannon J.M. Schizophrenia and related disorders. New York: Oxford University Press. 2017; 301 p.
  4. Laursen T.M., Nordentoft M., Mortensen P.B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 2014; 10: 425–448. doi: 10.1146/annurev-clinpsy-032813-153657.
  5. Wernlund A.G., Aagaard J. Excess mortality of schizophrenia. Ugeskr. Laeger. 2015; 177 (13): V10140556.
  6. Westman J., Eriksson S.V., Gissler M. et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol. Psychiatr. Sci. 2018; 27 (5): 519–527. doi: 10.1017/S2045796017000166.
  7. Wildgust H.J., Beary M. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J. Psychopharmacol. 2010; 24 (4): 37–50. doi: 10.1177/1359786810384639.
  8. Laursen T.M. Causes of premature mortality in schizophrenia: a review of literature published in 2018. Curr. Opin. Psychiatry. 2019; 32 (5): 388–393. doi: 10.1097/YCO.0000000000000530.
  9. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999; 35: S93–S100. doi: 10.1016/s0920-9964(98)00161-3.
  10. Gouzoulis-Mayfrank E., Walter M. Schizophrenia and addiction. In: Geert Dom, Franz Moggi (Editors). Co-occurring addictive and psychiatric disorders. A practice-based handbook from a European perspective. Berlin: Springer. 2015; 75–86.
  11. Thoma P., Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Rev. Psychiatry Clin. Neurosci. 2013; 67 (6): 367–383. doi: 10.1111/pcn.12072.
  12. Krystal J.H., D’Souza D.C., Gallinat J. et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox. Res. 2006; 10 (3–4): 235–252. doi: 10.1007/BF03033360.
  13. Li K.J., Chen A., DeLisi L.E. Opioid use and schizophrenia. Curr. Opin. Psychiatry. 2020; 33 (3): 219–224. doi: 10.1097/YCO.0000000000000593.
  14. Gouzoulis-Mayfrank E. Dual diagnosis psychosis and substance use disorders: theoretical foundations and treatment. Z. Kinder Jugendpsychiatr. Psychother. 2008; 36 (4): 245–253. doi: 10.1024/1422-4917.36.4.245.
  15. Mueser K.T., Gingerich S. Treatment of co-occurring psychotic and substance use disorders. Soc. Work Public Health. 2013; 28 (3–4): 424–439. doi: 10.1080/19371918.2013.774676.
  16. Coentre R., Talina M.C., Góis C., Figueira M.L. Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review. Psychiatry. Res. 2017; 253: 240–248. doi: 10.1016/j.psychres.2017.04.010.
  17. Whicher C.A., Price H.C., Phiri P. et al. Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial. Trials. 2019; 20 (1): 633. doi: 10.1186/s13063-019-3689-5.
  18. Spangaro M., Mazza E., Poletti S. et al. Obesity influences white matter integrity in schizophrenia. Psychoneuroendocrinology. 2018; 97: 135–142. doi: 10.1016/j.psyneuen.2018.07.017.
  19. Wang F., Xiang Y.-T., Ungvari G.S. et al. Prevalence of overweight in schizophrenia patients in Asia: findings of the research on Asian psychotropic prescription patterns (REAP) study. Int. J. Clin. Pharmacol. Ther. 2016; 54 (6): 450–455. doi: 10.5414/CP202526.
  20. Ono S., Sugai T., Suzuki Y. et al. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC. Psychiatry. 2018; 18 (1): 180. doi: 10.1186/s12888-018-1764-1.
  21. Jakobsen A.S., Speyer H., Nørgaard H.C.B. et al. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders — Baseline and two-years findings from the CHANGE trial. Schizophr. Res. 2018; 199: 96–102. doi: 10.1016/j.schres.2018.02.047.
  22. Mamakou V., Thanopoulou A., Gonidakis F. et al. Schizophrenia and type 2 diabetes mellitus. Psychiatriki. 2018; 29 (1): 64–73. doi: 10.22365/jpsych.2018.291.64.
  23. Schwenkreis P., Assion H.-J. Atypical antipsychotics and diabetes mellitus. World J. Biol. Psychiatry. 2004; 5 (2): 73–82. doi: 10.1080/15622970410029915.
  24. Hoffman R.P. The complex inter-relationship between diabetes and schizophrenia. Curr. Diabetes. Rev. 2017; 13 (3): 528–532. doi: 10.2174/1573399812666161201205322.
  25. Manu P., Dima L., Shulman M. et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta. Psychiatr. Scand. 2015; 132 (2): 97–108. doi: 10.1111/acps.12445.
  26. Goff D.C., Cather C., Evins A.E. et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry. 2005; 66 (2): 183–194; quiz 147, 273–274. doi: 10.4088/jcp.v66n0205.
  27. Lahti M., Tiihonen J., Wildgust H. et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol. Med. 2012; 42 (11): 2275–2285. doi: 10.1017/S0033291712000396.
  28. Attar R., Valentin J.B., Freeman P. et al. The effect of schizophrenia on major adverse cardiac events, length of hospital stay, and prevalence of somatic comorbidities following acute coronary syndrome. Eur. Heart J. Qual. Care Clin. Outcomes. 2019; 5 (2): 121–126. doi: 10.1093/ehjqcco/qcy055.
  29. Attar R., Johansen M.B., Valentin J.B. et al. Treatment following myocardial infarction in patients with schizophrenia. PLoS One. 2017; 12 (12): e0189289. doi: 10.1371/journal.pone.0189289.
  30. De Silva V.A., Suraweera C., Ratnatunga S.S. et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC. Psychiatry. 2016; 16 (1): 341. doi: 10.1186/s12888-016-1049-5.
  31. Goh K.K., Chen C.-H., Lu M.-L. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int. J. Psychiatry. Clin. Pract. 2019; 23 (1): 14–32. doi: 10.1080/13651501.2018.1449864.

Copyright (c) 2021 Sivolap Y.P., Portnova A.A., Yanushkevich M.V., Savchenkov V.A., Pushin P.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies